bioRxiv Science⌕ Search

bioRxiv · 10.1101/049247

Metabolic signatures of birth weight in 18288 adolescents and adults

Abstract

BackgroundLower birth weight is associated with increased susceptibility to cardiometabolic diseases in adulthood, but the underlying molecular pathways are incompletely understood. We examined associations of birth weight with a comprehensive metabolic profile measured in adolescents and adults.\n\nMethodsHigh-throughput nuclear magnetic resonance metabolomics and biochemical assays were used to quantify 87 circulating metabolic measures in seven cohorts from Finland and the United Kingdom comprising altogether 18 288 individuals (mean age 26 years, range 15-75). Metabolic associations with birth weight were assessed by linear regression models adjusted for sex, gestational age, and age at blood sampling. The metabolic associations with birth weight were compared to the corresponding associations with adult body mass index (BMI).\n\nResultsLower birth weight was adversely associated with cardiometabolic biomarkers, including lipoprotein subclasses, fatty acids, amino acids, and markers of inflammation and impaired liver function (P<0.0015 for 46 measures). Associations were consistent across cohorts with different ages at metabolic profiling, but the magnitudes were weak. The pattern of metabolic deviations associated with lower birth weight resembled the metabolic signature of higher adult BMI (R2=0.77). The resemblance indicated that 1-kg lower birth weight is associated with similar metabolic aberrations as caused by 0.92-units higher BMI in adulthood.\n\nConclusionLower birth weight is associated with adverse biomarker aberrations across multiple metabolic pathways. Coherent metabolic signatures between lower birth weight and higher adult adiposity suggest potentially shared underlying molecular mechanisms. However, the magnitudes of metabolic associations with birth weight are modest in comparison to the effects of adiposity, implying that birth weight is only a weak indicator of metabolic risk in adulthood.\n\nKEY POINTSO_LILower birth weight is adversely associated with a wide range of established and emerging circulating cardiometabolic biomarkers in adulthood, including lipoprotein subclasses and their lipids, fatty acid balance, amino acids, and markers of inflammation and liver function.\nC_LIO_LIThe metabolic associations are consistent across a wide age span from adolescence to retirement age, and similar for men and women.\nC_LIO_LIThe magnitudes of metabolic aberrations are weak for the variation in birth weight observed in general population cohorts. Although the metabolic associations with birth weight are statistically significant, they are likely to be of minor public health relevance.\nC_LIO_LIThe overall metabolic association pattern with lower birth weight closely resembles the metabolic signature of higher adult adiposity, suggesting that shared underlying metabolic pathways may be involved.\nC_LIO_LI1-kg lower birth weight ({approx}2 SD) is associated with similar adverse metabolic effects as caused by 0.92 higher BMI ({approx}0.25 SD) in adulthood. These findings indicate that fetal growth, as assessed by birth weight, only has minor effects on the adult metabolic risk profile in general population settings.\nC_LI

Source connections

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Peter Wurtz, Qin Wang, Marjo Niironen, Tuulia Tynkkynen, Mika Tiainen, Fotios Drenos, Antti J Kangas, Pasi Soininen, Michael Skilton, Kauko Heikkila, Anneli Pouta, Mika Kahonen, Terho Lehtimaki, Richard J Rose, Eero Kajantie, Markus Perola, Jaakko Kaprio, Johan Eriksson, Olli Raitakari, Debbie A Lawlor, George Davey Smith, Marjo-Riitta Jarvelin, Mika Ala-Korpela, Kirsi Auro. 2016-04-18. Metabolic signatures of birth weight in 18288 adolescents and adults. https://doi.org/10.1101/049247

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Personalized Immunotherapy via Multiscale Tumor-Immune Modeling and Optimal Control

Cancer remains a global health challenge requiring sophisticated understanding of tumor-immune dynamics for effective treatment design. Mathematical oncology has emerged as a rapidly evolving interdisciplinary field that uses mathematical models to enhance our understanding of cancer dynamics, including tumor growth, metastasis, and treatment response. This paper presents a comprehensive multiscale framework integrating patient-specific data, machine learning, and optimal control for personalized immunotherapy design. We develop a hybrid model that combines deterministic dynamics with stochastic elements and time delays, capturing the inherent variability and temporal lags in biological processes. The model incorporates biologically realistic Holling Type-II functional responses and is validated against longitudinal clinical data from 100+ cancer patients and patient-derived organoid experiments. Using deep neural networks with Bayesian regularization, we learn patient-specific parameter distributions from clinical biomarkers and predict treatment responses with high accuracy. Our optimal control framework, incorporating clinical constraints and toxicity limits, generates personalized treatment protocols that stabilize otherwise unstable dynamics. The framework establishes a new paradigm for precision immuno-oncology, bridging mathematical theory, computational methods, and clinical practice. Author summaryCancer remains one of the leading causes of death worldwide, and the immune system plays a crucial role in controlling tumor growth. However, the complex interactions between tumor cells and immune cells make it difficult to predict how individual patients will respond to immunotherapy. In this work, we develop a mathematical framework that integrates patient-specific data, machine learning, and optimal control to design personalized immunotherapy strategies. Our model captures the realistic dynamics of tumor-immune interactions by incorporating biologically relevant features such as time delays (representing immune response lags) and stochastic effects (representing biological variability). Using deep learning, we estimate patient-specific parameters from clinical biomarkers, enabling personalized predictions of treatment outcomes. We validate our framework against data from over 100 cancer patients and patient-derived organoid experiments, demonstrating excellent agreement. Our optimal control approach generates personalized treatment protocols that stabilize otherwise unstable tumor dynamics, achieving 78% tumor reduction compared to 52% for standard-of-care protocols. These findings suggest that therapies targeting immunological thresholds may be as important as those directly killing tumor cells, providing a new perspective for immunotherapy design. This framework bridges mathematical theory, computational methods, and clinical practice, offering a pathway toward truly personalized cancer treatment.

Systems Biology↗

Reversible Opto-Chemical activation of KRASG12V signaling with near single-cell precision

KRAS mutations drive some of the most lethal carcinomas, and genomic and inducible systems have established many of the cellular and tissue-level consequences. However, these approaches operate at the level of oncogene expression, allowing for cellular adaptation that masks the individual role of KRAS oncoprotein signaling. Here, we developed a reversible Opto-Chemical system to activate KRAS signaling by chemically translocating a cytosolic mutant KRASG12V G-domain to the plasma membrane upon light or small-molecule input. In MDCK cells, the G-domain plasma membrane recruitment activated downstream signaling and reduced collective migration. In mouse small Intestinal Organoids, G-domain recruitment promoted increased crypt size and number under Epidermal Growth Factor-deprived conditions. We further showed that the increased number of crypts depended on continuous KRASG12V signaling. Finally, under the same deprived conditions, localized activation in just one budding crypt promoted crypt formation compared to controls. This system decouples oncoprotein activity from oncogene expression, allowing to investigate the KRAS signaling contribution to early epithelial transformation.

Systems Biology↗

Mammalian aging involves genome-wide splicing degeneration leading to functional decline

Alternative splicing exhibits significant changes during development and aging, affecting the composition and variance in the transcriptome. However, it is unclear whether and how age-associated splicing dysregulation leads to functional consequences. Here, an integrative analysis of transcriptome data across mouse and human tissues revealed that aging is characterized by systematic deterioration of the fidelity of RNA splicing, here termed splicing degeneration, a measure of functional alteration of reading frame and domain configuration of protein products. Genes with higher aging-associated splicing degeneration were more conserved and enriched for processes such as RNA metabolism and antigen presentation. By assessing alternative splicing events associated with functional deterioration, we quantified the degree of splicing degeneration. Its level increased with age but was alleviated following calorie restriction or rapamycin treatment, indicating that it can serve as a new molecular hallmark of aging. Mechanistically, through a comprehensive meta-data analysis, we discovered that splicing degeneration is associated with age-associated changes in specific splicing factors, which in turn showed a strong association with age-related transcriptome changes. Overall, our study demonstrates the intricate relationship between aging and genome-wide splicing degeneration, revealing a promising target for aging interventions acting to reverse splicing degeneration.

Systems Biology↗